Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioadaptives (BDPT) Equity Average (2019 - 2025)

Bioadaptives' Equity Average history spans 7 years, with the latest figure at -$1.8 million for Q4 2025.

  • Quarterly results put Equity Average at -$1.8 million for Q4 2025, down 9.97% from a year ago — trailing twelve months through Dec 2025 was -$1.8 million (down 9.97% YoY), and the annual figure for FY2025 was -$1.8 million, down 15.54%.
  • Equity Average for Q4 2025 was -$1.8 million at Bioadaptives, down from -$1.3 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of -$1.2 million in Q4 2021 to a low of -$1.8 million in Q3 2024.
  • The 5-year median for Equity Average is -$1.5 million (2022), against an average of -$1.5 million.
  • The sharpest move saw Equity Average tumbled 32.73% in 2021, then increased 26.59% in 2025.
  • Year by year, Equity Average stood at -$1.2 million in 2021, then crashed by 32.19% to -$1.5 million in 2022, then grew by 8.36% to -$1.4 million in 2023, then fell by 17.07% to -$1.6 million in 2024, then fell by 9.97% to -$1.8 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at -$1.8 million, -$1.3 million, and -$1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.